13 completed, 3 recruiting, 3 unknown. 19 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 13, Recruiting 3, Unknown 3 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Vortioxetine: new trials by email Literature Review of Vortioxetine trials Research Report on Vortioxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vortioxetine for Newly Diagnosed Glioblastoma Vortioxetine - Glioblastoma | Phase 2 | Recruiting | University of Zurich | 78 | 2026-06-24 | 2026-06-29 |
| Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study Risk managment, Dasatinib, Quercetin (dietary supplement) - Aging, Cognitive Decline | Phase 2 | Completed | Washington University School of Medicine | 23 | 2025-07-28 | 2026-08-19 |
| Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia Vortioxetine - Fronto-temporal Dementia, Fronto-temporal Lobar Dementia | Phase 2 | Recruiting | Johns Hopkins University | 50 | 2025-03-20 | 2026-03-09 |
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) Fluoxetine, Sertraline, Vortioxetine - Depression, Sequestra | Phase 1 / Phase 2 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 520 | 2023-02-20 | 2026-01-27 |
| Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia Vortioxetine, Usual Antipsychotic Treatment - Cognitive Impairment With Primary Psychotic Disorder, Negative Symptoms With Primary Psychotic Disorder | Phase 2 / Phase 3 | Unknown | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 37 | 2022-01-20 | 2024-02-26 |
| Vortioxetine for Post-COVID-19 Condition Vortioxetine, Placebo - Post-COVID-19 Condition, Post-COVID-19 Syndrome | Phase 2 | Completed | Brain and Cognition Discovery Foundation | 149 | 2021-09-16 | 2025-01-16 |
| Vortioxetine for Treatment of Depressive Mood and Alcohol Use Vortioxetine, Acamprosate - Depressive Disorder, Major, Alcoholism | Phase 2 | Unknown | Hanyang University Seoul Hospital | 128 | 2019-01-25 | 2020-08-05 |
| Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression Vortioxetine infusion 25 mg, Vortioxetine tablets 10 mg/day, Placebo infusion - Major Depressive Disorder | Phase 2 | Completed | H. Lundbeck A/S | 80 | 2018-12-03 | 2019-08-29 |
| Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression Vortioxetine, Placebo - Bipolar Disorder Depression | Phase 2 | Unknown | Seoul National University Hospital | 100 | 2018-08-08 | 2018-08-10 |
| Substance Misuse To Psychiatric Disorders for Cannabis Vortioxetine, Treatment as Usual - Cannabis Use Disorder, Depressive State | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 37 | 2018-07-25 | 2023-07-05 |
| THINC-it Vortioxetine - Sensitivity to Change Vortioxetine, THINC-it Tool - Major Depressive Disorder, Cognitive Change | Phase 2 / Phase 3 | Completed | Brain and Cognition Discovery Foundation | 158 | 2017-05-24 | 2025-06-08 |
| Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder Vortioxetine (IV), Placebo (IV), Vortioxetine (tablet) - Depressive Disorder, Major | Phase 2 | Completed | H. Lundbeck A/S | 55 | 2016-09-27 | 2018-06-20 |
| Vortioxetine for Binge Eating Disorder Vortioxetine, Placebo - Binge Eating Disorder | Phase 2 | Completed | University of Chicago | 80 | 2016-06-01 | 2020-11-23 |
| Investigating the Effect of Vortioxetine in Adult ADHD Patients vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | H. Lundbeck A/S | 227 | 2014-12-01 | 2018-03-07 |
| Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder vortioxetine (Lu AA21004), Duloxetine, Placebo - Depressive Disorder, Major | Phase 2 | Completed | Takeda | 602 | 2012-04-01 | 2015-02-05 |
| Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder Vortioxetine - Depressive Disorder, Anxiety Disorder | Phase 2 | Completed | H. Lundbeck A/S | 48 | 2012-04-01 | 2017-03-16 |
| Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder Vortioxetine, Placebo - Depressive Disorder, Major | Phase 2 / Phase 3 | Completed | Takeda | 600 | 2010-11-01 | 2013-12-18 |
| Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults Vortioxetine (Lu AA21004) - Major Depressive Disorder | Phase 2 | Completed | H. Lundbeck A/S | 74 | 2007-06-01 | 2014-01-29 |
| Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults Placebo, Vortioxetine (Lu AA21004), Venlafaxine XL - Major Depressive Disorder | Phase 2 | Completed | H. Lundbeck A/S | 426 | 2006-08-01 | 2014-05-13 |
Depressive Disorder, Major (8) · Depression (3) · Anxiety Disorders (2) · Cognitive Dysfunction (2) · Depressive Disorder (2) · Alcoholism (1) · Attention Deficit Disorder with Hyperactivity (1) · Binge-Eating Disorder (1) · Bipolar Disorder (1) · Cognition Disorders (1) · Fatigue (1) · Frontotemporal Dementia (1) · Glioblastoma (1) · Marijuana Abuse (1) · Mental Fatigue (1)
H. Lundbeck A/S (6) · Brain and Cognition Discovery Foundation (2) · Takeda (2) · First Affiliated Hospital of Chongqing Medical University (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Hanyang University Seoul Hospital (1) · Johns Hopkins University (1) · Seoul National University Hospital (1) · The University of Hong Kong (1) · University of Chicago (1) · University of Zurich (1) · Washington University School of Medicine (1)
United States (6) · Finland (3) · Germany (3) · South Korea (3) · Bulgaria (2) · Canada (2) · Estonia (2) · Hong Kong (2) · Latvia (2) · Poland (2) · Russia (2) · Ukraine (2) · China (1) · Croatia (1) · India (1)
Albert KK Chung, MBBS(HK) (1) · Benedicto Crespo Facorro, Professor (1) · Christopher Morrow, MD (1) · Eric Lenze, MD (1) · Jon E Grant, JD, MD, MPH (1) · Roger McIntyre (1) · Roger S. McIntyre, MD, FRCPC (1) · Sungwon Roh (1) · Yong Min Ahn, MD, PHD (1)
PMID 21767441, PMID 28213121, PMID 28858412, PMID 29035574, PMID 29235884, PMID 29546401, PMID 29689693, PMID 30439678, PMID 30766492, PMID 31094901, PMID 31404802, PMID 31422713, PMID 32670103, PMID 32784346, PMID 36708956, PMID 37891522, PMID 38114867, PMID 38424537, PMID 38520501, PMID 38860901, PMID 38954402
2015 (1), K23AG088248 (1)